This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2024, the FDA approved Flyrcado for patients with known or suspected coronaryarterydisease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. 2023 Oct, 82 (16) 15981610.
15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S. The LCDs have a future effective date of Nov. 24, 2024.
The new code, designated by The American Medical Association ( AMA ), supports FFRCT as the standard of care in assessing patients with suspected coronaryarterydisease ( CAD ). In the hospital setting, CMS increased payment for the FFRCT service by ~7% for 2024.
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronaryarterydisease (CAD), making it a valuable tool for clinicians.
Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. J Am Geriatr Soc. 2023;71(7): 2052-2081. Newby LK, LaPointe NM, Chen AY, et al.
About Chronic Myocardial Ischemia with Refractory Angina Chronic myocardial ischemia occurs in the setting of coronaryarterydisease when there is reduced blood flow to the heart. million patients in the United States.
I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronaryarterydisease, we expect to see this trend really impact the way CT is used in the future.” “The CT procedural mix is evolving, and cardiac CT is starting to account for a large proportion of that.
25, 2025 GE HealthCare has delivered the first patient doses of Flyrcado(flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronaryarterydisease (CAD), at early adopter imaging centers in the US. tim.hodson Mon, 03/03/2025 - 16:07 Feb.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content